Samjennix Experiences 10% Forced Liquidation After Leverage Launch, KOSPI Falls 3%
After the launch of Samjennix's leverage product, investors faced a 10% forced liquidation, leading to over a 10% drop in its stock price due to foreign and institutional selling. On the same day, the KOSPI dropped by 3%, while the KOSDAQ managed to recover above the 860 level. HLB also recorded a limit down due to FDA's request for additional documentation.
Shortly after the launch of Samjennix's single stock leverage product, some investors faced a 10% forced liquidation. This triggered a surge in selling pressure for the stock.
The combined selling from foreigners and institutions caused Samjennix's stock price to drop by more than 10%. This sharp decline prompted additional liquidations of single stock leverage positions in the market.
Other stocks holding single stock leverage products also fell in tandem, setting new low prices. Concerns were raised about the realization of a 'negative compounding' phenomenon in related products.
HLB recorded a limit down after the U.S. FDA requested additional documents regarding Rivoseranib. This announcement heightened volatility within the stock.
On the same day, the KOSPI index fell by 3%. During the same time, the KOSDAQ recovered above the 860 mark.
Korea Investment & Securities announced that it expects SK Hynix's second-quarter operating profit to fall short of market expectations. This forecast impacted stock prices across the semiconductor sector.
Exchanges and securities firms indicated that they are conducting investor protection and risk management through related disclosures. Additional announcements and performance report schedules are being closely monitored.